Episode Details

ImmunityBio just took a 17% nosedive today, but the headline numbers are masking pure Wall Street irony. Despite posting a massive 53% surge in quarterly revenue and scoring a major FDA label expansion for its flagship cancer drug, Anktiva, investors hit the panic button over a ballooning $184.6 million net loss. In this episode of Implied, we break down why over $100 million of that loss is simply a non-cash accounting quirk tied to the stock's past performance—and why the market's reaction might actually be a massive opportunity for bounce players. Is Wall Street completely mispricing ImmunityBio’s widening commercial runway? Tune in for the full story behind today's misunderstood drop.